The 2020 Edition of the White Paper on Pharmaceutical Representation has just been released in Japan

third batch of state-owned mining will land this month, the affected pharmaceutical companies have previously set the manpower program, now also to the implementation of the node, which means that this two months, many people have to find work again.Most of these companies have better friends, it is not good to directly say some of the company's situation, Big Mimi today chatted about the changes on the Japanese side of our country.Yesterday, the Japan Pharmaceutical Representative Certification Center released the 2020 Edition of the White Paper on Pharmaceutical Representatives, with 57,158 medical representatives in Japan as of March 31, 2020, a decrease of 2,742 from last year and a record annual decrease.The number of medical representatives in Japan last year was 59,900, and after peaking at 65,752 in 2013, the number of medical representatives in Japan has been decreasing every year since then, with the total number of people falling by more than 5,000 in the last two years due to the early retirement policies implemented by the departments, and last year's results were shared, falling below 60,000 for the first time, and this year's results show more turnover.However, CSO's pharmaceutical representation increased by 303 from last year to 3,917.The Japan Pharmaceutical Representative Certification Center sent questionnaires to 185 pharmaceutical companies, including 67 companies of the Japan Pharmaceutical Association, 34 companies of the Generics Association, 87 other companies, in addition to pharmaceutical companies, the survey also included 14 CSO companies, 1 commercial company, the survey period from March to August this year, the questionnaire recovery rate is 100%.Specifically, 140 of them are domestic pharmaceutical companies in Japan, the total number of pharmaceutical representatives is 33,463, down 1992 from last year, 45 foreign pharmaceutical companies, the total number of pharmaceutical representatives is 19711, 1052 fewer than last year, and 14 CSO companies increased by 303, commercial companies are 67 people, down 1 person from last year.In addition, 56,058 of this year's total number of pharmaceutical representatives are certified by the Japan Pharmaceutical Representative Certification Center, i.e., the Japanese Pharmaceutical Representative Certification Rate is 98.1%.The root cause of the reduction has been mentioned many times before, out of the environment changes, in terms of the Japanese market, before and after 2000 pharmaceutical representative activities or to increase SOV-based, so more medical representatives are needed to increase the number of visits, but then slow-disease drugs in 2015 after the patent expired Entering the low-cost drug market, at the same time, the main products of research and development pharmaceutical companies to cancer, CNS, rare diseases, marketing promotion also shifted to the MR×e model, medicine on behalf of the traditional promotion of F2F part of the shift to multi-channel digital content, and so on, these changes led to reduced demand for employment.As we all know, the transmission of the latest medical information can not be separated from the representative of medicine, then, the industry can maintain the best number of people? According to the Japanese industry forecast that this trend of continuous decline will continue, by 2025, the number of Japanese medical representatives will remain at 50,000, by 2030, there may be another 40,000 people.Japanese medical representatives used to be able to do it as a career for life, but the two years have changed a lot, and if there are eventually 40,000 people left in a decade's time, then the people who leave may be over 50 now, but then they should retire naturally, and the representatives in their 30s and 40s are unlikely to leave, and they will be able to stay in the industry.In general, although Japan is also facing changes in the structure of medicines, is also implementing drug price reform, to promote the professionalization of pharmaceutical representatives, but the impact on this group is not too great.Back in our country, due to the large group of pharmaceutical representatives, the age of employees is also low, relatively speaking, competition is greater, with VBP, representative filing, etc. , pharmaceutical representatives will be more professional, while the number of practitioners decreased, in the impact of industry changes, representatives of any age will face the fate of re-employment.A person is in an industry, live in the rise and fall of an industry, when the environment changes, practitioners composition, business patterns, competitiveness will undergo a major change, have a strong adaptability will stay, or the inherent thinking and acting people will inevitably leave actively or passively.Everyone should think, five or ten years from now, will you be the one who will remain in the industry? (Pharmaceutical representative)